Quantcast

Latest Prednisone Stories

2012-05-17 12:19:23

A hormone-depleting drug approved last year for the treatment of metastatic prostate cancer can help eliminate or nearly eliminate tumors in many patients with aggressive cancers that have yet to spread beyond the prostate, according to a clinical study to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO), June 1-5, in Chicago. The phase II clinical trial, led by investigators at Dana-Farber Cancer Institute and other research centers, examined the use...

2012-01-27 11:24:48

Stopping immunosuppressive prednisone soon after transplantation found safe Highlights:     Patients who quickly stop taking the immunosuppressant prednisone after receiving a kidney transplant avoid experiencing serious prednisone-related side effects.     This rapid discontinuation of prednisone does not jeopardize the long-term survival of patients and their new organs.     Approximately 16,500 patients receive kidney transplants each...

2011-07-07 06:00:00

TARRYTOWN, N.Y., July 7, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 3 VENICE clinical trial evaluating the investigational agent ZALTRAP(TM) (aflibercept) in the first-line treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer will continue to completion as planned, with no modifications due to efficacy or to safety concerns. This decision is based on the recommendation of an Independent Data...

2011-06-17 21:06:39

Trial found no major safety concerns; larger studies needed A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy. These results are encouraging, but larger studies are needed to further investigate the safety and efficacy of etanercept. Results of this clinical trial are available in Annals of Neurology, a journal published by Wiley-Blackwell on behalf of...

2011-06-03 06:30:00

CHICAGO, June 3, 2011 /PRNewswire/ -- Data related to ZYTIGA(TM) (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The studies were sponsored by Ortho Biotech Oncology Research & Development, unit of Cougar Biotechnology, Inc. "We are pleased that these data have been selected for presentation at the 2011 ASCO Annual Meeting," said William N. Hait, M.D., Ph.D., Global Therapeutic Area Head, Ortho Biotech...

2011-05-25 16:26:00

HORSHAM, Pa., May 25, 2011 /PRNewswire/ -- A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA(TM) (abiraterone acetate) plus prednisone compared to patients treated with prednisone plus placebo. The COU-AA-301...

2011-04-28 14:04:00

HORSHAM, Pa., April 28, 2011 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved ZYTIGA(TM) (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel. Androgens are hormones that promote the development and maintenance of male sex characteristics....


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'